Science and Research

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).

Study details
Study-ID: NCT06154837, 2023-506880-32
Study-ID: NCT06154837, 2023-506880-32
DZL Disease Area: COPD
DZL Disease Area: COPD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN, BREATH
DZL Participating Sites: ARCN, BREATH
Start Date: 27.11.2023
Completion Date: 26.06.2026
Status: Terminated
Status: Terminated
DZL recruiting center, DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.